Vanguard Group's Updated Ownership in Myriad Genetics Inc

The Vanguard Group has filed an amendment to its Schedule 13G, reporting its updated ownership in Myriad Genetics Inc. As of September 30, 2025, Vanguard holds 7,882,515 shares, representing 8.47% of the company's common stock. This marks a decrease of 1,374,978 shares from its previous filing, reflecting a 14.85% reduction in its holdings. The value of Vanguard's investment in Myriad Genetics is approximately $63,375,420.60, a 28.92% increase from its prior valuation. Vanguard's clients, including investment companies and managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The filing certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing the control of the issuer.